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Epilepsy is the fourth most common neurological condition characterized by 
recurrent unprovoked seizures. Chronic and recurrent seizures may give rise to cell 
necrosis, astrocyte activation, neuron death, reactive oxygen species (ROS) produc-
tion, and mitochondria dysfunction. Recent studies have shown that cell-based 
therapy is a promising treatment option for epilepsy. Various stem cell types were 
used for treatment of epilepsy in basic and experimental researches. It is especially 
vital to gauge the efficacy of distinct donor cell types, such as the embryonic stem 
cells and induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), 
hippocampal precursor cells, γ-aminobutyric acid-ergic progenitors, neural stem 
cells. The goal of this chapter is to evaluate the progress made hitherto in this area 
and to discuss the prospect for cell-based therapy for epilepsy.
Keywords: epilepsy, seizures, mesenchymal stem cells, neural stem cell 
transplantation
1. Introduction
Epilepsy is a neurological disorder, characterized by recurrent (two or more) 
epileptic seizures resulting from excessive and abnormal cortical neural activity. 
There are tens of millions people experiencing epilepsy [1]. Causes of epilepsy are 
complex, such as a toxic ingestion, serious head injury, stroke, tumor, complications 
of other brain diseases and genetic mutation. Epilepsy may occur after some brain 
infections such as meningitis, herpes simplex encephalitis, pork tapeworm (cysticer-
cosis), cerebral malaria, toxoplasmosis, and toxocariasis. Genetics is believed to be 
involved in the majority of cases, either directly or indirectly. Around 0.095% of all 
deaths are on account of status epilepticus or seizure [2]. Approximately 30% of epi-
leptic patients have temporal lobe epilepsy(TLE) which causes neuronal cell death, 
aberrant mossy fiber sprouting (MFS) [3], hippocampal damage [4] and cognitive 
deteriorations [5]. The past 30 years have seen the introduction of over fifteen kinds 
of third-generation antiepileptic drugs (AEDs) that provide more options for differ-
ent types of seizures [6]. However, approximately 30% of patients continue to have 
process of epilepsies [7, 8]. For drug-resistant epilepsy, AEDs are unable to prevent 
or reverse the process of disease. The treatment was not effective [9]. Furthermore, 
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the patients that respond to AEDs typically experience adverse systemic side effects, 
underscoring the urgent need to develop new therapies that target epileptic foci 
rather than more systemic interventions.
Based on the high incidence of this disease and the limited treatment options 
available, it makes sense to explore and analyze the new treatment strategies to 
inhibit or prevent epileptic-related neuronal changes. Due to the potential for 
providing neuroprotection, diminishing inflammation and curbing epileptogen-
esis of Mesenchymal stem cells, the development of chronic epilepsy typified by 
spontaneous seizures and learning and memory impairments may be restrained. 
In this chapter, the efficacy of MSCs to restrain neurodegeneration, inflammation, 
and epileptogenesis were discussed [10]. Neural stem cells and neural progenitors 
(NSC/NPCs) have broad application prospect in neuro-restorative therapy due 
to their survival of intracerebral grafting, remarkable capacity for self-renewal, 
release a multitude of neurotrophic factors, plasticity, and ability to integrate into 
host brain circuitry [11]. This paper reviewed different cell sources and strategies 
of using MSC and progenitor cells to treat epilepsy by establishing new neurons 
that incorporate into host brain circuits.
2. Mesenchymal stem cells and epilepsy
2.1 Properties of mesenchymal stem cells
MSCs were discovered in bone marrow in 1966 for the first time [12]. The 
therapeutic potential of bone marrow mesenchymal stem cell (BMSC) transplanta-
tion has recently been investigated in various pathological conditions of the central 
nervous system (CNS) [13–16]. Subsequently, MSCs were widely and gradually 
isolated from various tissues, including adipose, tooth root, umbilical cord, muscle 
[17–19]. For more scientific comparison and contrast of research results, the 
minimal criteria for MSCs was defined by the International Society for Cellular 
Therapy (ISCT) including plastic adherent growth, express CD105, CD73 and 
CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79 or CD19 and 
HLA-DR surface molecules [20]. MSC were able to differentiate into adipocytes, 
cardiomyocytes, chondrocytes, osteocytes, and myoblasts, both in vitro and in vivo. 
Early studies showed that MSC can differentiate into CNS glia and neurons and 
express neural cell markers in vivo. In addition, these cells are readily available as 
donor cells because MSCs can be obtained freshly from human umbilical cord, bone 
marrow and cord blood. MSCs or MSC-like cells can also be amplified from fresh 
and frozen samples of several other tissues.
2.2 MSC-based therapy for epilepsy
Some evidence shows that MSC secretes a large number of cytokines and growth 
factors through a paracrine mechanism to stimulate endogenous protection and 
recovery responses [21, 22]. In addition, mesenchymal stem cells express gene-
encoded proteins, which are involved in a variety of biological activities, including 
immunity, angiogenesis, and neuronal functions [23]. After an experimental 
stroke in rats, intravenous injection of human mesenchymal stem cells can enhance 
the production of neurotrophins and reduce the death of ischemic tissue [24]. 
Direct implantation of human mesenchymal stem cells into the hippocampus of 
mice can induce the proliferation, migration, differentiation and neurogenesis of 
endogenous neural stem cells [25]. Mesenchymal stem cells have neuroprotective 
properties by enhancing the antioxidant effect of cells in nerve cells in vitro. At the 
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same time, they also show immunomodulatory effects in vitro, including inhibiting 
the maturation of dendritic cells and the proliferation of T cells and B cells [26]. 
Mesenchymal stem cells have the ability to transdifferentiate into nerve cells and 
have the properties of immune regulation and neuroprotection. Thus, mesenchymal 
stem cells are involved in many physiological and pathological processes, including 
cell homeostasis, aging, tissue damage, and inflammatory diseases.
A number of approaches have been tested using cell therapy in epilepsy models 
(Table 1). The pilocarpine model of rat epilepsy is the most common model in 
the study, because it is similar to the characteristics of human epilepsy. After the 
injection of pilocarpine, the animal has cholinergic effects, seizures and subsequent 
chronic epilepsy symptom. 3 × 106 rat autologous BMSCs in 500 μl PBS were injected 
intravenously to adult male Sprague–Dawley rats 24 and 36 hours after the first 
seizure. The results of the behavioral test revealed that the number of seizures in 
the treatment group was significantly reduced. The histopathology of untreated rat 
tissue showed cell death and neurophagy. The digital density of neurons in each area 
was significantly higher in the treated group than in the untreated group [27].
Gianina Teribele Venturin et al. found that bone marrow mononuclear cells 
(BMMCs) transplantation to chronic epileptic rats via tail vein injection decreased 
the frequency of spontaneous recurrent seizures (SRS), prevented the learning and 
memory deterioration [28]. In that work, 1 × 107 cells were administered 22 days 
after Status epilepticus (SE). Here, they showed for the first time that BMMCs 
reduced the frequency but not the duration of SRS. To evaluate whether BMMCs can 
reverse the cognitive deficits, the Morris water maze was used to test spatial mem-
ory. A 60-s probe test confirmed that lithium–pilocarpine impairs the acquisition of 
spatial memory and that BMMCs reverse this effect. In other words, Transplantation 
of BMMCs improved the learning and long-term spatial memory impairments after 
cell transplantation. This is a pioneering study providing behavioral evidence sup-
porting cell-based therapy for chronic epilepsy. Further research is needed to clarify 
the mechanism by which transplanted cells exert their effects.
Another study in a mouse model examined the effects of intravenous route of 
EGFP transgenic mice or male Wistar rats BM-derived MSCs [29]. Transplantation 
of BMCs prevents spontaneous seizures in pilocarpine-treated rats. They also 
examined the electrophysiological properties of rat brain sections from the different 
experimental groups. In saline-epileptic animals, the field excitatory postsynaptic 
potentials (fEPSPs) by stimulation of Schaffer’s vein was reduced 10 days after 
SE compared with the non-epileptic rats in the control group; however, an incre-
mental increase in fEPSPs amplitude was observed in the BMC-epileptic animals. 
Qualitative analysis of Nissl-stained neurons showed histological lesions in the 
epileptic rats including neuron shrunken, pycnotic nuclei and severe reduction in 
the neuronal density. The digital density of neurons in each area was significantly 
higher in the treated group than in the untreated group. After transplantation, cells 
were localized in the cortex and/or hippocampus, perirhinal cortex and basomedial 
amygdale. In addition, no tissue damage or tumor formation was found in animals 
transplanted with BMSCs, and no systemic complications or increased morbidity 
occurred in epileptic animals with intravenous BMSCs.
Several studies have also examined the bystander effects of the mesenchymal 
stem cells that modulate the host environment. Daejong Jeon et al. demonstrate that 
a cytosolic extract of human ASCs (ASCs-E) mitigated the activity of seizure spikes 
following diazepam treatment and inhibited SRS in mice [30]. The evidence indicates 
that ASCs-E can effectively regulate the pathogenesis in epilepsy models and improved 
behavioral performance. They also suggest a stem cell–based, noninvasive therapy for 
the treatment of epilepsy. Further investigation of the capability of MSCs for anticon-
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Table 1. 
Stem cell transplantation studies in epilepsy models.
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The results of Filip et al. [31] clearly demonstrated that gabapentin enhances 
GABA-ergic neurotransmission and reduced the severity of epilepsy caused by 
PTZ kindling. Their results showed that the injection of mesenchymal stem cells 
enhanced the level of GABA inhibitory neurotransmitter and had a greater reduc-
tion in the severity of epilepsy [32]. In addition, research results showed that MSCs 
can not only improve the severity of seizures and oxidative stress damage, but also 
improve pentylenetetrazol (PTZ)-induced motor incoordination and cognitive 
impairment. These functions may benefit from the ability of mesenchymal stem 
cells to migrate and return to damaged areas, and self-renewal and differentia-
tion potential for neuronal death during epilepsy [33, 34]. In this study, they also 
found that the expression of microglia and neuronal markers were increased after 
injections of MSCs, which can be clearly seen from the immunohistochemical 
expression of the glial cell marker S100β protein. Previous studies have reported 
that mesenchymal stem cells can differentiate into glial cell-like cells in phenotype 
and function, and can be used as a suitable glial cell substitute for nerve repair and 
regeneration in clinical applications [35]. In addition, transplanted cells can provide 
a large amount of neurotrophic factors including brain-derived neurotrophic factor, 
nerve growth factor, and neurotrophic factor-3 [36]. In conclusion, MSCs could be 
a promising therapeutic option in the management of chronic epilepsy.
Indeed, a follow-up study using a mouse model of status epilepticus demon-
strated that transplantation of human umbilical mesenchymal stem cells (HUMSCs) 
into bilateral hippocampi ameliorated seizure activity [37]. They examined the 
effects of intra-hippocampal transplantation of HUMSCs on pilocarpine-treated 
rats. The results of video and electroencephalography (EEG) recordings from two 
to four week after PBS injection or HUMSC implantation showed that pilocarpine-
induced SE in terms of onset, incidence, and duration were attenuated. In addition, 
other pathological changes after pilocarpine-induced SE such as brain edema, 
hippocampal cytoarchitecture, and integrity of the hippocampal pyramidal neurons 
were evaluated. Magnetic resonance imaging [MRI] was performed on each rat at 
one week before SE and one, eight, 15, 22, and 29 days afterward. The edema in the 
lateral ventricles, piriform cortex, and hippocampus at eight days was similar to that 
at one day after HUMSCs transplantation. Then, histo-morphologically on Nissl 
stained coronal sections was performed to examine possible changes in the cytoar-
chitecture. The dorsal hippocampus was significantly enlarged in the SE + HUMSC 
group than those in the SE group, suggesting the neuroprotective potential of trans-
planted HUMSCs. In general, intra-hippocampal transplantation of HUMSCs can 
prevent tissue damage and neuronal loss, provide supplemental neuronal protection 
and stimulate neurogenesis, and suppress the spontaneous recurrent seizures in a 
pilocarpine TLE model.
Another study examined the effects of implantation of Bone marrow derived 
mesenchymal stem cells either through intravenously (IV) or in hippocampus 
bilaterally (IC). BMSCs treatment reduced the hippocampal excitatory amino 
acid neurotransmitters, downregulated inflammatory cytokines (TNF-α, IL-1β), 
ameliorated histological changes, and reduced oxidative insult and inflammatory 
markers [38]. After 22 days of Pilocarpine induction of status epilepticus [SE], 
intrahippocampal injection of BMSCs was performed. Hippocampal GABA content 
is lower in SE epileptic animals than the sham control group. BMSCs transplanta-
tion through both routes significantly elevated hippocampal GABA content as 
compared to SE rats. In addition, the frequency of epileptic seizures in video sur-
veillance analysis showed a significant reduction in the number of animals injected 
with MSC compared with the carrier group.
One study reported that BMSCs transplantation reduced hippocampal excitatory 
amino acid neurotransmitters and inhibited BDNF-mediated excitatory toxicity 
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by either I.V. or I.C. pathways, similar to inhibition of synaptophysin immune 
response. The observed improvements extended to neurotransmitter balance, in 
which inhibitory tension was increased and excitatory metastases were observed in 
rats with epilepsy restored to normal balance. Bone marrow mesenchymal stem cell 
therapy improved the neurochemical and histological changes induced by triclosan, 
retained amino acid neurotransmitters to normal levels, down-regulated immune 
responses to insulin growth factor 1 receptors, synaptophysin, and caspase-3, 
and reduced detection of oxidative damage and inflammatory markers in epilep-
tic models.
The number of GAD67+ GABAergic inhibitory neurons was significantly 
decreased in the CA1 and DH regions in the vehicle group at 2 months after SE 
inducing by the lithium-pilocarpine [39]. Furthermore, both Manganese-enhanced 
magnetic resonance imaging (MEMRI) and Timm (zinc) staining showed that the 
abnormal mossy fiber sprouting of the hippocampus in the MSC group was lower. 
Therefore, their results showed that intravenous infusion of bone marrow mesen-
chymal stem cells reduced the occurrence of epilepsy by inhibiting abnormal MFS 
in the SE rat model. Moreover, previous research has focused on reducing the loss of 
inhibitory neurons as a therapeutic mechanism for infused mesenchymal stem cells. 
Injection of mesenchymal stem cells inhibited the onset of epilepsy after SE and 
retained cognitive function. Injected GFP+ MSCs accumulated in the hippocampus 
and were related to the preservation of GAD67+ and NeuN+ hippocampal neurons.
3. Neural stem/progenitor cell and epilepsy
3.1 Potential of NSC/NPC for epilepsy
Epilepsy affects 1%-2% of the population worldwide [40]. Approximately 40% 
of epilepsy patients have temporal lobe epilepsy (TLE). Up to 35% of patients 
with TLE continue to have chronic seizures due to resistant to antiepileptic drugs 
[41, 42]. TLE is characterized by complex partial seizures hippocampal sclerosis, 
inhibitive gamma aminobutyric acid-ergic (GABAergic) interneuron loss, gliosis in 
hippocampal [43]. The main pathological changes of human temporal lobe epilepsy 
are hippocampal sclerosis and mossy fiber sprouting (MFS). Hippocampal sclerosis 
is mainly manifested in morphology as hippocampal atrophy and induration, and 
in histology, it is mainly manifested as necrosis of selective CA3 pyramidal neurons 
and secondary glial fibrosis. Mossy fibers (MF) are the axons of granular cells in the 
dentate gyrus, which normally project to the dendrites of pyramidal neurons in the 
CA3 and CA4 regions. MFS means that the postsynaptic site of MF is vacant and 
the target area of its normal projection disappears, resulting in budding to the inner 
molecular layer after the death of pyramidal neurons in these areas [44]. At the 
molecular level, the imbalance of excitatory and inhibitory neurotransmitters may 
be the main factor of seizures.
Although surgical removal of the hippocampus decreased seizure activity, this 
choice is bound to cognitive impairment [45], loss of viable tissue during resec-
tion [46], hemiplegia, hemianopia, and memory impairment. Bilateral resection 
is not suitable for patients with bilateral hippocampal sclerosis. Therefore, explor-
ing through neural stem cells transplantation for the repair and reconstruction of 
hippocampal function has important clinical significance. Hence, the development 
of alternative therapies that have the potential for both reversing the epileptogenic 
circuitry and suppressing chronic epileptic seizures is extremely valuable.
Neural stem cells exist in the nervous system. After transplantation into the 
damaged central nervous system, they may differentiate into nerve neurons, 
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astrocytes and oligodendrocytes by asymmetric division. Release of chemokines 
after partial tissue injury attracts neural stem cells to the site of injury. Neural 
stem cells also secrete a variety of neurotrophic factors to promote the repair of 
damaged cells.
Neural stem cells contribute to strengthen synaptic connections and create new 
neural circuits. It is proved that the directional differentiation of neural stem cells 
makes the repair and replacement of dead nerve cells possible. In order to reduce 
the sequelae of nerve injury, delay or inhibit the further development of the disease, 
and achieve better recovery effect, it is very necessary to repair and activate necrotic 
nerve cells fundamentally.
Neural stem cells have the capacity of self-renewal and express various growth 
factors. Multipotent NSCs can be obtained from multiple sources such as embryonic 
stem cells (ESCs), induced pluripotent stem cells (iPSCs), fetal, postnatal and 
adult brain tissues [47, 48]. NSCs can survive well intracerebral grafting, migrate 
into regions of the brain displaying neuron loss, increase concentration of proin-
flammatory cytokines, positively influence the survival of host cells and tissues, 
replace significant numbers of lost interneurons, promote functional recovery and 
 maintain normal network function [49, 50].
3.2 Efficacy of neural stem/progenitor cell grafts in rat model
Astrocytes have the capable of secreting beneficial neurotrophic factors 
that promote neuroprotection, reduce frequencies of SRMS [51] and enhance 
neurogenesis. It provides an attractive approach for stimulation neurogenesis 
endogenous NSCs in the dentate subgranular zone [52, 53]. NSC transplantation 
can suppress neuroinflammation. Therefore, neural stem cells become potential 
donor cells for the treatment of brain injury or neurodegenerative diseases. 
Transplantation of NSCs in hippocampal injury rat is efficacious for thwarting 
mood and memory dysfunction and abnormal neurogenesis [54]. Studies have 
shown that in animal models with TLE seizures, the number of hippocampal 
GABA-ergic interneurons decreased [55, 56]. Status epilepticus [SE] typically 
progresses into temporal lobe epilepsy [TLE].
Several studies have examined the efficacy of NSCs for controlling seizures 
when administered in SE model (Table 2). A study reported that the transplant 
intravenously of beta galactosidase-encoded human NSCs could prevent sponta-
neous recurrent seizure formation in adult rats with pilocarpine-induced status 
epilepticus [57]. Ruschenschmidt et al. [58] have demonstrated that embryonic 
stem cell-derived neurons displayed intrinsic and synaptic properties characteristic 
of neurons when transplanted into the hippocampus of chronic epileptic animals. 
Transplantation techniques using bilaterally placed grafts of striatal precursors 
in the acute phase of the disease reduced the frequency of spontaneous recurrent 
motor seizures (SRMS) on a long-term basis in the chronic epilepsy period [59]. 
Adult neural stem cells had anti-epileptic effect in rats with status epilepticus (SE) 
induced by kainic acid. NSC transplantation increased the number of neuropeptide 
Y (NPY) and glutamic decarboxylase 67 (GAD67) positive interneurons, and 
inhibited the moss fiber germination to the inner molecular layer [60, 61].
Hong Shen et al. [62] demonstrated that Hippocampal stem cells (HSCs) derived 
from the postnatal hippocampus have the potential of promoting repairs in the 
epileptic brain. In this study, Hippocampal stem cells were transplanted into the 
right hippocampus in rats with kainite acid [KA]-induced epilepsy. At 1, 4, 8, and 
24 weeks posttransplantation, Timm’s stain, Nissl staining, electroencephalogram 
were performed. The results showed that sharp waves were reduced, Aberrant MFS 
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Table 2. 
Stem cell transplantation studies in epilepsy models.
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neurons was partially restored. Given these results, HSC grafts have the therapeutic 
potentials for the treatment of epilepsy. Further investigation of the capability of 
NSCs for providing neuroprotection using a maximum electroconvulsive shock 
(MES) mode showed matching results [63]. Transplantation of medial ganglionic 
eminence (MGE) cells altered the course of MES acute onset, increased the onset 
threshold, and increased GABA interneuron selectivity compensates for excitatory 
activity, thereby reducing susceptibility to epileptic seizures.
Over the past decades, embryonic stem cells, neural stem cells, or neural 
precursors have been tested in rat models of epilepsy: Li-pilocarpine-induced 
status epilepticus, kainic acid-induced status epilepticus or kindling-based TLE 
models. Haejin Lee et al. investigated whether transplantation of human fetal 
brain-derived NSPC grafts into the hippocampus in both kindling and pilocarpine 
induced TLE models could improve the epileptic phenotypes [64]. In the study, 
huNSPCs for transplantation were derived from a cadaver at 13 weeks of gesta-
tion. In vitro, huNSPCs can differentiate into three types of nerve cells in vitro: 
neurons, oligodendrocytes, and astrocytes. Differentiation of human NSPCs was 
analyzed at 8 weeks posttransplantation in epileptic rats. Confocal microscopic 
images revealed that grafted cells differentiated into oligodendrocytes, astrocytes 
and TUJ1+ neurons in kindled rats. In the pilocarpine model, TUJ1+ neurons, 
GFAP+ astrocytes, and OLIG2+ oligodendrocyte progenitors were observed in 
confocal microscopy images. In the kindled rats, EEG examination, behavioral 
seizure duration, and seizure stage were substantial decreased. Nevertheless, the 
anticonvulsant effect is not persistent and gradually disappeared after 7 weeks. The 
frequency and severity of spontaneous recurrent motor seizures (SRMS) were sig-
nificantly reduced at 2 and 3 months after grafting in epileptic rats. Furthermore, 
the average total time spent in SRMS was significant decreased at 2 and 3 months 
after grafting. Timm staining show that aberrant sprouting of mossy fibers was 
not significantly different between the two groups. Water maze testing and probe 
test were performed at 9 weeks after grafting. The ability of spatial learning and 
memory function in kindled rats showed no significant difference. Another study 
examined the effects of transplantation of NPCs from three different donor species 
[65]. Clonic seizure thresholds were analyzed by statistical evaluation. Average 
clonic seizure threshold increased above pre-grafting control were observed during 
this time-point investigation after grafting.
3.3 GABA-ergic progenitors/neuron and epilepsy
Interneurons are a type of nerve cells that can release neurotransmitters such 
as GABA. They mainly exist in brain areas such as the cerebral cortex and hip-
pocampus [66]. Interneurons account for about 25% to 30% of the total number of 
brain neurons [67] and play an important role in the regulation of brain functions. 
Gamma-amino butyric acid (GABA) intermediate neurons refer to nerve cells 
with GABA as the main transmitter, accounting for about 20% of total neurons in 
cerebral cortex [68]. GABA intermediate neurons form extensive synaptic con-
nections with pyramidal cells and play an important role in regulating the activity 
of pyramidal cells and maintaining the excitatory/inhibitory balance of cerebral 
cortical circuits [69, 70]. In the cerebral cortex, different types of neurons form 
complex circuits and work together to process and store information in a timely 
manner. They also interact with glutamate pyramidal cell input in specific ways 
and support the temporal dynamics of synapses, network oscillations, selection of 
cell combinations, and realization of brain states. This cellular diversity gives the 
ability to perform complex biological processes. The relatively uniform pyramidal 
cells are supported by a rich variety of GABAergic interneurons, which provide 
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general inhibition and also regulate pyramidal cell activity over time. The type of 
GABAergic interneuron is not unique to the CA1 region. Similar neurons are also 
present in the hippocampus and most other areas of the foreign cortex [71]. In 
addition, these GABAergic inter-neurons can also be found in the cortex of mice, 
rats, cats, monkeys and humans. Examination of epileptic tissue removed from TLE 
patients revealed a loss of interneurons that release inhibitory neurotransmitter 
GABA [72, 73]. GABA-mediated inhibition has been repeatedly demonstrated to be 
weakened in TLE animal models [74] (Table 3).
Several studies have tested the effects of neurons. Neural transplantation of GABA-
producing cells into subthalamic nucleus (STN) aims to correct imbalance between 
excitatory and inhibitory neurotransmission. Grafting of GABA-producing cells into 
the STN suppressed seizure activity. The STN can be considered a target region [75]. 
hPSC-derived maturing GABAergic interneurons suppressed seizures and ameliorated 
behavioral abnormalities such as cognitive deficits, aggressiveness, and hyperactivity. 
In addition, substantial numbers of the GABA-ergic interneurons and GDNF-secreting 
cells mediate seizure suppression. Neural cell grafting has shown considerable effi-
ciency for inducing the reactivation of the host hippocampal GABA-ergic interneurons 
and diminishing the aberrant mossy fiber sprouting in the dentate gyrus. Furthermore, 
the synaptic integration of graft-derived GABA-ergic interneurons effects host brain 
activity at both cellular and network levels.
4. Challenges and potential
Currently, MSC-based therapy and Neural stem cell and neurons grafting for 
epilepsy has become an increasing focus of research. Stem cells can be targeted 
to focal areas of epileptogenesis and tailored to affect only the dysfunctional 
constituents of the epileptic circuit. Stem cells could theoretically be used in areas 
of eloquent cortex and could be more widely inserted into a region of epilepto-
genesis based on clinical response. Neural stem cells can engraft into the injured 
brain areas, positively influence the survival of host cells and tissues, and promote 
functional recovery. Afterward, function of these cells for suppressing seizures and 
improving cognitive function in chronic epilepsy were determined.
Stem cell therapy for epilepsy mainly involves the replacement of damaged neu-
rons with stem cell differentiation, secretion of protective factors and anti-inflam-
matory factors to prevent clinical deterioration. Mesenchymal stem cells have great 
potential in cell therapy because they are easy to obtain, easy to amplify, and can be 
autologous transplanted with little immune rejection. There is ample evidence that 
mesenchymal stem cells can differentiate into neuronal destinies and secrete a range 
of anti-inflammatory, protective cytokines. In addition, bone marrow mesenchymal 
stem cells have been shown to point to damaged areas, meaning they could be used as 
vehicles for therapeutic drugs. In fact, various beneficial effects have been reported 
after transplantation of human bone marrow mesenchymal stem cells into rodent 
models of epilepsy, such as neurotrophic factor-mediated protection, enhanced 
neurogenesis, inflammation regulation, and removal of abnormal protein aggregates.
At present, the application of NSCs to repair central nervous system damage 
mainly takes two ways, namely exogenous transplantation replacement therapy and 
endogenous activation complementary therapy. Therefore, the function of NSCs to 
treat neurological diseases is of great significance, and certain progress has been exam-
ined in experimental research on the treatment of temporal lobe epilepsy. NSCs have 
the capacity of self-renewing, highly migratory, low immunogenic, and differentiate 
into different types of nerve cells. In theory, it overcomes many of the above shortcom-
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neurons formed dense axonal 
arborizations in the inner 
molecular layer and throughout 
the hilus
Table 3. 
Stem cell transplantation studies in epilepsy models.
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A number of experimental studies have shown that cell transplantation can 
reduce the attack frequency of TLE, inhibit the pathological process of epilepsy, 
and repair the damaged nerve structure. However, several key problems still need to 
be solved before cell transplantation therapy for epilepsy can move from preclinical 
research to clinical research. This means that grafted cells should meet the following 
requirements.
(1) The activity of transplanted cells should be guaranteed normal physiological 
activities. They can establish functional synaptic connections with the host and 
carry out functional integration to meet the requirements of repairing damaged 
neural pathways; (2) the transplanted cells have a strong ability to migrate from the 
transplanted area to the appropriate cell layer; and (3) the transplanted cells should 
have normal differentiation and proliferation ability.
In view of the therapeutic effect of different cell types, application of combined 
strategies may be considered. This may include transplanting MSC and nerve cells 
(hippocampus or MGE progenitors or NSCs) into the hippocampus: (1) systemic 
administration of hippocampal neurogenesis enhancers such as small molecules, 
antidepressants, antioxidants, or neurotrophic factors; (2) MSC and Neural stem 
cells engineered to release neurogenic enhancers and adenosine. Enhancing the 
overall rate of transplantation-derived GABA-ergic intermediate neuron and GDNF 
derived cells has enormous potential to significantly reduce the neurogenic regional 
recovery of the hippocampus in the pre-clinical models of chronic frame [77, 78].
5. Conclusions
To sum up, it is of great significance to explore the way of cell transplantation, 
find a treatment method that can replace the lost neurons, repair the damaged 
nervous system, increase the secretion of inhibitory neurotransmitter, and effec-
tively control the occurrence and development of epilepsy. At the same time, the 
method can overcome the shortcomings of drug treatment and surgical treatment, 
fundamentally cure epilepsy. MSC and Progenitors/Stem cell derived from multiple 
sources can reduce epileptogenesis and improved cognitive function with graft-
ing performed to epileptic brain regions. This has been demonstrated in animal 
prototypes of chronic TLE, kindling, SE and absence seizures, and in mutant mice 
displaying SRS. These abundant studies have laid a solid foundation for the early 
application of cell transplantation therapy in clinical practice.
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ROS reactive oxygen species
BBB damage of blood–brain barrier
iPSCs induced pluripotent stem cells
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MSCs mesenchymal stem cells
TLE temporal lobe epilepsy
MFS mossy fiber sprouting
AEDs antiepileptic drugs
NSC neural stem cells
NPC neural progenitors
BMSC bone marrow mesenchymal stem cell
CNS central nervous system
ISCT International Society for Cellular Therapy
BMMCs bone marrow mononuclear cells
SRS spontaneous recurrent seizures
SE status epilepticus
fEPSPs excitatory postsynaptic potentials
ASCs-E extract of human ASCs
PTZ pentylenetetrazol
HUMSCs human umbilical mesenchymal stem cells
EEG electroencephalography
MRI magnetic resonance imaging
IV intravenously
IC hippocampus bilaterally
MEMRI manganese-enhanced magnetic resonance imaging
MF mossy fibers
ESCs embryonic stem cells
SRMS spontaneous recurrent motor seizures
NPY neuropeptide Y
GAD67 glutamic decarboxylase 67
KA kainite acid
HSCs hippocampal stem cells
MES maximum electroconvulsive shock
MGE medial ganglionic eminence
huNSPCs human neural stem/progenitor cells
TUJ1 β-tubulin III
STN subthalamic nucleus
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